Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 280

1.

MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.

Jin Y, Sun PL, Kim H, Seo AN, Jheon S, Lee CT, Chung JH.

Ann Surg Oncol. 2014 Feb;21(2):621-8. doi: 10.1245/s10434-013-3355-1. Epub 2013 Nov 9.

PMID:
24212721
2.

Clinicopathologic and prognostic significance of c-MYC copy number gain in lung adenocarcinomas.

Seo AN, Yang JM, Kim H, Jheon S, Kim K, Lee CT, Jin Y, Yun S, Chung JH, Paik JH.

Br J Cancer. 2014 May 27;110(11):2688-99. doi: 10.1038/bjc.2014.218. Epub 2014 May 8.

3.

ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.

Zhang Y, Sun Y, Li Y, Fang Z, Wang R, Pan Y, Hu H, Luo X, Ye T, Li H, Wang L, Chen H, Ji H.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S577-82. doi: 10.1245/s10434-013-3027-1. Epub 2013 Jun 18.

PMID:
23775406
4.

Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.

Yanagawa N, Leduc C, Kohler D, Saieg MA, John T, Sykes J, Yoshimoto M, Pintilie M, Squire J, Shepherd FA, Tsao MS.

J Thorac Oncol. 2012 Oct;7(10):1513-21.

5.

Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma.

Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P.

Cancer Cytopathol. 2013 Sep;121(9):500-7. doi: 10.1002/cncy.21288. Epub 2013 Mar 12.

6.

Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.

Kim MH, Shim HS, Kang DR, Jung JY, Lee CY, Kim DJ, Lee JG, Bae MK, Kim HR, Lim SM, Kim EY, Park JS, Chung KY, Kim HJ, Kim JH, Cho BC.

Lung Cancer. 2014 Mar;83(3):389-95. doi: 10.1016/j.lungcan.2014.01.003. Epub 2014 Jan 14.

PMID:
24462463
7.

Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.

Metro G, Chiari R, Bennati C, Cenci M, Ricciuti B, Puma F, Flacco A, Rebonato A, Giannarelli D, Ludovini V, Bellezza G, Ferolla P, Minotti V, Crinò L.

Clin Lung Cancer. 2014 Jan;15(1):86-92. doi: 10.1016/j.cllc.2013.08.002. Epub 2013 Oct 17.

PMID:
24139827
8.

Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.

de Melo AC, Karen de Sá V, Sternberg C, Olivieri ER, Werneck da Cunha I, Fabro AT, Carraro DM, de Barros e Silva MJ, Pimenta Inada HK, de Mello ES, Soares FA, Takagaki T, Ferreira CG, Capelozzi VL.

Oncology. 2015;89(3):175-86. doi: 10.1159/000376552. Epub 2015 Apr 1.

PMID:
25833149
9.

ROS1 gene rearrangement and copy number gain in non-small cell lung cancer.

Jin Y, Sun PL, Kim H, Park E, Shim HS, Jheon S, Kim K, Lee CT, Chung JH.

Virchows Arch. 2015 Jan;466(1):45-52. doi: 10.1007/s00428-014-1679-2. Epub 2014 Nov 6. Erratum in: Virchows Arch. 2015 Jul;467(1):123.

PMID:
25374304
10.

Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas.

Sholl LM, Weremowicz S, Gray SW, Wong KK, Chirieac LR, Lindeman NI, Hornick JL.

J Thorac Oncol. 2013 Mar;8(3):322-8. doi: 10.1097/JTO.0b013e31827db604.

11.

Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.

Schneider CP, Heigener D, Schott-von-Römer K, Gütz S, Laack E, Digel W, Guschall WR, Franke A, Bodenstein H, Schmidtgen C, Reck M.

J Thorac Oncol. 2008 Dec;3(12):1446-53. doi: 10.1097/JTO.0b013e31818ddcaa.

12.

Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.

Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K, Yasumoto K.

J Thorac Oncol. 2010 May;5(5):591-6. doi: 10.1097/JTO.0b013e3181d0a4db.

13.

Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification.

Noro R, Honda K, Tsuta K, Ishii G, Maeshima AM, Miura N, Furuta K, Shibata T, Tsuda H, Ochiai A, Sakuma T, Nishijima N, Gemma A, Asamura H, Nagai K, Yamada T.

Ann Oncol. 2013 Oct;24(10):2594-600. doi: 10.1093/annonc/mdt293. Epub 2013 Jul 30.

PMID:
23899839
14.

Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.

Kim HR, Shim HS, Chung JH, Lee YJ, Hong YK, Rha SY, Kim SH, Ha SJ, Kim SK, Chung KY, Soo R, Kim JH, Cho BC.

Cancer. 2012 Feb 1;118(3):729-39. doi: 10.1002/cncr.26311. Epub 2011 Jun 30.

15.

Differences in the survival of patients with recurrent versus de novo metastatic KRAS-mutant and EGFR-mutant lung adenocarcinomas.

Yu HA, Sima CS, Hellmann MD, Naidoo J, Busby N, Rodriguez K, Riely GJ, Kris MG.

Cancer. 2015 Jun 15;121(12):2078-82. doi: 10.1002/cncr.29313. Epub 2015 Mar 17.

16.

High expression of Sonic hedgehog signaling proteins is related to the favorable outcome, EGFR mutation, and lepidic predominant subtype in primary lung adenocarcinoma.

Kim JE, Kim H, Choe JY, Sun P, Jheon S, Chung JH.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S570-6. doi: 10.1245/s10434-013-3022-6. Epub 2013 May 26. Erratum in: Ann Surg Oncol. 2013 Dec;20 Suppl 3:S755.

PMID:
23709101
17.

Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.

Xia N, An J, Jiang QQ, Li M, Tan J, Hu CP.

Exp Lung Res. 2013 Oct;39(8):328-35. doi: 10.3109/01902148.2013.819535. Epub 2013 Aug 6.

PMID:
23919423
18.

Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.

Sun JM, Lira M, Pandya K, Choi YL, Ahn JS, Mao M, Han J, Park K, Ahn MJ, Kim J.

Lung Cancer. 2014 Feb;83(2):259-64. doi: 10.1016/j.lungcan.2013.11.009. Epub 2013 Nov 20.

PMID:
24300132
19.

Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients.

Tanaka A, Sueoka-Aragane N, Nakamura T, Takeda Y, Mitsuoka M, Yamasaki F, Hayashi S, Sueoka E, Kimura S.

Lung Cancer. 2012 Jan;75(1):89-94. doi: 10.1016/j.lungcan.2011.06.004. Epub 2011 Jul 5.

PMID:
21733594
20.

Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.

Planck M, Isaksson S, Veerla S, Staaf J.

Clin Cancer Res. 2013 Sep 15;19(18):5116-26. doi: 10.1158/1078-0432.CCR-13-0928. Epub 2013 Aug 12.

Supplemental Content

Support Center